Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224504 | 1.00 | RIPK1 (0.72) | RIPK1GAAKMT2AMAPTKDM4E | |
| SCHEMBL20640756 | 0.84 | RIPK1 (1.00) | RIPK1KMT2AMEN1 | |
| SCHEMBL20640677 | 0.84 | RIPK1 (1.00) | RIPK1KMT2AMEN1 | |
| SCHEMBL20641141 | 0.84 | RIPK1 (1.00) | RIPK1KMT2AMEN1 | |
| SCHEMBL20221886 | 0.82 | RIPK1 (0.74) | RIPK1POLBLMNA | |
| SCHEMBL20213598 | 0.82 | RIPK1 (0.74) | RIPK1ALDH1A1POLB | |
| SCHEMBL31389495 | 0.80 | RIPK1 (0.44) | RIPK1GAAKMT2AMAPTKDM4E | |
| SCHEMBL29294624 | 0.79 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL30014928 | 0.79 | RIPK1 (0.57) | RIPK1GAAKMT2AMAPTKDM4E | |
| SCHEMBL18367181 | 0.79 | RIPK1 (0.57) | RIPK1GAAKMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548484-B1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-11607396-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4095138-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| US-20220339129-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-10-27 | — | — | US | disclosed |
| CN-110023313-B | Bicyclic amide compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3555093-B1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-110072863-B | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10933036-B2 | — | — | 2021-03-02 | — | — | US | disclosed |
| EP-3548484-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018109097-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607396-B2 | Bicyclic amide compounds and methods of use thereof | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885GAA 2107/4885KMT2A 1607/4885 |
| US-20220339129-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885GAA 2107/4885KMT2A 1607/4885 |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885GAA 2297/4885KMT2A 2986/4885 |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885GAA 2107/4885KMT2A 1607/4885 |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885GAA 2107/4885KMT2A 1607/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885GAA 2297/4885KMT2A 2986/4885 |
| US-10933036-B2 | — | CYP1B1, CYP4B1, CYP11B2 | RIPK1 4591/4885GAA 1056/4885KMT2A 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.